Small‐molecule inhibitors of human 2OG oxygenases other than JMJD6 are in clinical use, demonstrating the therapeutic viability of 2OG oxygenase inhibition.[25–27] For example, inhibitors of the hypoxia‐inducible factor‐α (HIF‐α) prolyl hydroxylase domain‐containing proteins (PHDs) are used for long‐term treatment of chronic kidney disease (CKD)‐associated anemia,[27] and Mildronate, an inhibitor of γ‐butyrobetaine hydroxylase (BBOX),[28, 29–30] is used as a cardioprotective agent.[26]. Here, BBOX1 is linked to chronic kidney disease.